Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;5(4):112-5.
doi: 10.1016/j.jyp.2013.12.002. Epub 2013 Dec 30.

Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis

Mageshwaran Lakshmanan  1 , Alphienes Stanley Xavier  1
Affiliations
Review

Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis

Mageshwaran Lakshmanan et al. J Young Pharm. 2013 Dec.

Abstract

Increasing incidence of MDR-TB, long duration of treatment and co-infection with HIV are the significant problems in achieving the eradication of tuberculosis. Bedaquiline is an anti-tuberculosis drug with unique mechanism of action. It selectively inhibits the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis like active, dormant, replicating, non-replicating, intracellular and extracellular. Preclinical studies have shown the efficacy of bedaquiline in terms of reduction in bacterial load and treatment duration. Phase II clinical studies have established the safety, tolerability and earlier sputum conversion time in patients with MDR-TB. In 2012 FDA approved bedaquiline for treatment of MDR-TB and XDR-TB.

Keywords: ATP synthase inhibitor; Bedaquiline; MDR-TB; Tuberculosis; XDR-TB.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO Global Tuberculosis Report. WHO; 2013. http://www.who.int/tb/publications/global_report/en/ [Internet]. [cited 2013 Nov 27]. Available from: - PubMed
    1. WHO Treatment of Tuberculosis: Guidelines for National Programmes [Internet]. WHO. [cited 2013 Nov 27]. Available from: http://www.who.int/tb/publications/tb_treatmentguidelines/en/.
    1. Spigelman M., Woosley R., Gheuens J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2010;14:663–664. - PubMed
    1. Berney M., Cook G.M. Unique flexibility in energy metabolism allows mycobacteria to combat starvation and hypoxia. PLoS One. 2010;5:e8614. - PMC - PubMed
    1. Tran S.L., Cook G.M. The F1Fo-ATP synthase of Mycobacterium smegmatis is essential for growth. J Bacteriol. 2005;187:5023–5028. - PMC - PubMed